AR117844A1 - Derivados de tiazolopiridina como antagonistas del receptor de adenosina - Google Patents

Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Info

Publication number
AR117844A1
AR117844A1 ARP200100134A ARP200100134A AR117844A1 AR 117844 A1 AR117844 A1 AR 117844A1 AR P200100134 A ARP200100134 A AR P200100134A AR P200100134 A ARP200100134 A AR P200100134A AR 117844 A1 AR117844 A1 AR 117844A1
Authority
AR
Argentina
Prior art keywords
antagonists
adenosine receptor
thiazolopyridine derivatives
thiazolopyridine
derivatives
Prior art date
Application number
ARP200100134A
Other languages
English (en)
Inventor
Alejandro Crespo
Schiemann Kai Dr
Tanzer Eva-Maria Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR117844A1 publication Critical patent/AR117844A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente se refiere a derivados de tiazolopiridina que se incluyen en la fórmula general (1), y al uso de los compuestos de la presente para el tratamiento y/o la prevención de enfermedades y trastornos hiperproliferativos o infecciones en mamíferos, especialmente humanos, y a composiciones farmacéuticas que contienen tal compuesto. Reivindicación 1: Compuesto caracterizado porque se selecciona del grupo que consiste en: @@@@@@@@@
ARP200100134A 2019-01-22 2020-01-20 Derivados de tiazolopiridina como antagonistas del receptor de adenosina AR117844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19152961 2019-01-22

Publications (1)

Publication Number Publication Date
AR117844A1 true AR117844A1 (es) 2021-09-01

Family

ID=65199346

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100134A AR117844A1 (es) 2019-01-22 2020-01-20 Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Country Status (12)

Country Link
US (1) US20220119412A1 (es)
EP (1) EP3914600A1 (es)
JP (1) JP2022524914A (es)
KR (1) KR20210116572A (es)
CN (1) CN113939520A (es)
AR (1) AR117844A1 (es)
AU (1) AU2020211697A1 (es)
CA (1) CA3127284A1 (es)
IL (1) IL285024A (es)
MX (1) MX2021008510A (es)
SG (1) SG11202107858WA (es)
WO (1) WO2020152132A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022258622A1 (en) 2021-06-07 2022-12-15 Ares Trading S.A. Combination treatment of cancer
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024028273A1 (en) 2022-08-02 2024-02-08 Merck Patent Gmbh Novel crystalline forms of (s)-7-oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2h-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide and co-crystal forms thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207554A (en) 1972-08-04 1980-06-10 Med-El Inc. Method and apparatus for automated classification and analysis of cells
US4125828A (en) 1972-08-04 1978-11-14 Med-El Inc. Method and apparatus for automated classification and analysis of cells
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1221444B1 (en) 1999-07-02 2005-08-31 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
JP3886897B2 (ja) * 2000-06-21 2007-02-28 エフ．ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
EP1301498A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
AU2002356962C1 (en) 2001-12-12 2008-05-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
EP1618108A2 (en) 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
RU2351597C2 (ru) * 2003-05-19 2009-04-10 Ф.Хоффманн-Ля Рош Аг Производные бензотиазола в качестве лигандов аденозиновых рецепторов
AU2004274154A1 (en) * 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
RU2382782C2 (ru) 2004-07-22 2010-02-27 Ф. Хоффманн-Ля Рош Аг Производные бензотиазола
CN110636846B (zh) * 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
FI3661941T3 (fi) * 2017-08-01 2023-03-23 Merck Patent Gmbh Tiatsolopyridiinijohdannaisia adenosiinireseptoriantagonisteina

Also Published As

Publication number Publication date
US20220119412A1 (en) 2022-04-21
IL285024A (en) 2021-09-30
EP3914600A1 (en) 2021-12-01
CA3127284A1 (en) 2020-07-30
JP2022524914A (ja) 2022-05-11
KR20210116572A (ko) 2021-09-27
SG11202107858WA (en) 2021-08-30
AU2020211697A1 (en) 2021-09-09
WO2020152132A1 (en) 2020-07-30
MX2021008510A (es) 2021-09-21
CN113939520A (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2019002150A1 (es) Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073)
UY37845A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CO2019014484A2 (es) Nuevos derivados de azaquinolina
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
UY37971A (es) Derivados de indol macrocíclicos sustituidos
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
ZA202001295B (en) Thiazolopyridine derivatives as adenosine receptor antagonists
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
CL2022002919A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CL2023002635A1 (es) Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias